Biomaterial-based vaccine induces regression of established intracranial glioma in rats

Pharmaceutical Research

Volumn 28, Issue 5, 2011, Pages 1074-1080

  Ali, Omar A ^a,b,c   Doherty, Ed ^a,b   Bell, William J ^a   Fradet, Tracie ^a   Hudak, Jebecka ^a   Laliberte, Marie Therese ^a   Mooney, David J ^a,b,c   Emerich, Dwaine F ^a  

^a InCytu Inc   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

brain tumor; cancer vaccine; glioma; immunotherapy; PLG

Indexed keywords

BIOMATERIAL; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; CANCER GROWTH; CANCER IMMUNIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; GLIOMA; GLIOMA CELL; HISTOPATHOLOGY; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CANCER VACCINES; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; OLIGODEOXYRIBONUCLEOTIDES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79955605774     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0361-x     Document Type: Article

References (23)

1. Legler JM, Gloeckler Ries LA, Smith MA, Warren JL, Heineman EF, Kaplan RS, Linet MS. Brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst. 1999;1382-90. (Pubitemid 29399996)
2. H Okada 2009 Brain tumor immunotherapy with type-1 polarizing strategies Ann NY Acad Sci 1174 18 23 19769732 10.1111/j.1749-6632.2009.04932.x 1:CAS:528:DC%2BD1MXhtlehs7rL
3. OM Grauer JW Molling E Benniink LW Toonen RP Sutmuller S Nierkens GJ Adema 2008 TLR ligands in the local treatment of established intracerebral murine gliomas J Immunol 181 6720 6729 18981089 1:CAS:528:DC%2BD1cXhtlaisr%2FM
4. OM Grauer P Wesseling GJ Adema 2009 Immunotherapy of diffuse gliomas: biological background, current status and future developments Brain Pathol 19 674 693 19744040 10.1111/j.1750-3639.2009.00315.x 1:CAS:528:DC%2BD1MXht12htL%2FK
5. J Banchereau RM Steinman 2007 Taking dendritic cells into medicine Nature 49 419 426 (Pubitemid 47509552)
6. K Holger B Frank E Hessel RL Coffman 2007 Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists Nat Med 13 552 559 10.1038/nm1589 (Pubitemid 46830615)
7. RE Nair YS Jong SA Jones A Sharma E Mathiowitz NK Egilmez 2006 IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity J Immunother 29 10 20 16365596 10.1097/01.cji.0000175489.19314.d2 1:CAS:528:DC%2BD2MXhtlagt7nO
8. JS Yu G Liu H Ying WH Yong KL Black CJ Wheeler 2004 Vaccination with tumor lysate-pulsed dendritic cells elicits antigen specific cytotoxic T cells in patients with malignant glioma Cancer Res 64 4973 4979 15256471 10.1158/0008-5472.CAN-03-3505 1:CAS:528:DC%2BD2cXls1Omt7o%3D (Pubitemid 38924545)
9. E Gilboa 2007 Dendritic cell based vaccines J Clin Invest 117 1195 1203 17476349 10.1172/JCI31205 1:CAS:528:DC%2BD2sXlt1Omtrc%3D (Pubitemid 46718404)
10. R Yamanaka T Abe N Yajima N Tsuchiya J Homma T Kobayashi M Narita M Takahashi R Tanaka 2003 Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial Br J Cancer 89 1172 1179 14520441 10.1038/sj.bjc.6601268 1:CAS:528:DC%2BD3sXns1Cmu7k%3D (Pubitemid 37363398)
11. M Ingram JG Buckwalter DB Jacques RM Freshwater GB Abts K Techy CH Miyagi RW Shelden LW Rand 1990 English, Immunotherapy for recurrent malignant glioma: an interim report on survival Neurol Res 12 265 273 1982172 1:STN:280: DyaK3M7psVygtQ%3D%3D
12. TM Allen PR Cullis 2004 Drug delivery systems: entering the mainstream Science 303 1818 1822 15031496 10.1126/science.1095833 1:CAS:528: DC%2BD2cXitFehu70%3D (Pubitemid 38374867)
13. H Brem S Piantadosi PC Burger M Walker R Selker NA Vick K Black M Sisti S Brem G Mohr, et al. 1995 Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas Lancet 345 1008 1012 7723496 10.1016/S0140-6736(95)90755-6 1:STN:280:DyaK2M3ktVansw%3D%3D
14. OA Ali N Huebsch L Cao G Dranoff DJ Mooney 2009 Infection-mimicking materials to program dendritic cells in situ Nat Mater 2 151 158 10.1038/nmat2357
15. OA Ali D Emerich G Dranoff DJ Mooney 2009 In Situ regulation of DC subsets and T Cells mediates tumor regression in mice Sci Transl Med 1 8 19
16. S Cohen T Yoshioka M Lucarelli LH Hwang R Langer 1991 Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres Pharm Res 8 713 720 2062800 10.1023/A:1015841715384 1:CAS:528:DyaK3MXksFOis74%3D
17. TP Richardson MC Peters AB Ennett DJ Mooney 2001 Polymeric system for dual growth factor delivery Nat Biotechnol 19 1029 1034 11689847 10.1038/nbt1101-1029 1:CAS:528:DC%2BD3MXot1ersL0%3D (Pubitemid 33041886)
18. DF Emerich DJ Mooney H Storrie RS Babu JH Kordower 2010 Injectable hydrogels providing sustained delivery of vascular endothelial growth factor are neuroprotective in a rat model of Huntington's disease Neurotox Res 1 66 74 10.1007/s12640-009-9079-0
19. Morrone FB, Oliveira DL, Gamermann P, Stella J, Wofchuk S, Wink MR, Meurer L, Edelweiss MI, Lenz G, Battastini AM. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer. 2006;226-32.
20. F Gu HM Younes AO El-Kadi, et al. 2005 Sustained interferon-gamma delivery from a photocrosslinked biodegradable elastomer JCR 102 3 607 617 1:CAS:528:DC%2BD2MXotVOjsQ%3D%3D (Pubitemid 40170204)
21. DA Zaharoff BS Hoffman HB Hooper, et al. 2009 Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12 Cancer Res 69 6192 6199 19638573 10.1158/0008-5472.CAN-09-1114 1:CAS:528:DC%2BD1MXpt1Cgtb0%3D
22. SS Neelapu S Baskar BL Gause, et al. 2004 Human autologous tumor-specific T-Cell responses induced by liposomal delivery of a lymphoma antigen Clin Cancer Res 24 8309 8317 10.1158/1078-0432.CCR-04-1071 (Pubitemid 40053391)
23. JA Hubbell SN Thomas MA Swartz 2009 Materials engineering for immunomodulation Nature 462 449 460 19940915 10.1038/nature08604 1:CAS:528:DC%2BD1MXhsVylsLzL